Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL).

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

Black Diamond Video’s Integrated Digital Surgical Suites to be installed at the Yale-New Haven Hospital

Black Diamond Video, Inc. announces that Yale-New Haven Hospital has selected BDV to install their state-of-the-art Integrated Digital Surgical Suites (IDSS) into their neurosurgical suite and gastrointestinal suites in the new Smilow Cancer Center.

9 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.

9 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

SEED Competition launched in China

Roche, OrbiMed, and McKinsey officially launched the SEED Competition at the Beijing International Healthcare Industry Forum today. This is one of the first life sciences business plan competitions in Greater China.

9 Nov 2009

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China.

9 Nov 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

9 Nov 2009

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

An analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology (ACAAI) 2009 Annual Meeting in Miami Beach.

9 Nov 2009

Cedars-Sinai Medical Center to expand support for doctors and patients on Guam

A team from Cedars-Sinai Medical Center will be meeting with leaders in medicine and health insurance and as well as patients during a visit to Guam this week.

7 Nov 2009

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.

7 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

PET scanning emerges as an important tool in the evaluation of lung cancer

A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting.

7 Nov 2009

Halozyme Therapeutics announces results of its insulin variability study

Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.

7 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

Oncology News and Research

Further Reading

EpiCept announces third quarter 2009 financial results

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

Black Diamond Video’s Integrated Digital Surgical Suites to be installed at the Yale-New Haven Hospital

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

CytRx reports financial results for the three months and nine months ended September 30, 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

SEED Competition launched in China

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

Cedars-Sinai Medical Center to expand support for doctors and patients on Guam

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Locus Pharmaceuticals creates a new division, Ansaris

PET scanning emerges as an important tool in the evaluation of lung cancer

Halozyme Therapeutics announces results of its insulin variability study

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News